logo_ProQR-150x150.png
ProQR Announces Results for the First Quarter of 2017
May 17, 2017 07:00 ET | ProQR Therapeutics
Key updates QR-010 Phase 1b clinical trial on track to present top-line data in cystic fibrosis (CF) patients in mid-2017.Investigational new drug (IND) application for QR-110, ProQR’s lead program...
ProQR remembers co-founder Henri Termeer after his unexpected passing
May 15, 2017 07:00 ET | ProQR Therapeutics
LEIDEN, the Netherlands, May 15, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), remembers co-founder and supervisory board member Henri A. Termeer, who unexpectedly passed away...
logo_ProQR-150x150.png
ProQR Announces R&D Day in New York on June 15
May 09, 2017 07:00 ET | ProQR Therapeutics
Key updates: ProQR to host an R&D day in New York on June 15 from 8:00am to 1:00pm ETPresentations on development programs: QR-010 for cystic fibrosis, QR-110 for Leber’s congenital amaurosis...
logo_ProQR-150x150.png
ProQR to Present its Ophthalmology Pipeline at ARVO, Highlighting Programs in Leber’s Congenital Amaurosis Type 10 (LCA 10) and Usher Syndrome
May 01, 2017 07:00 ET | ProQR Therapeutics
Key updates At ARVO ProQR will present additional positive pre-clinical proof-of-concept (PoC) data for QR-110 targeting LCA 10. The company has recently received IND clearance to start clinical...
logo_ProQR-150x150.png
ProQR Announces Clearance of IND Application to Start Clinical Trial for QR-110 in Leber’s Congenital Amaurosis Type 10 Patients
April 27, 2017 07:00 ET | ProQR Therapeutics
Key updates With the clearance of the investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA), ProQR can now start clinical development of QR-110 in Leber’s...
logo_ProQR-150x150.png
ProQR to Present at the Deutsche Bank Health Care Conference
April 20, 2017 07:00 ET | ProQR Therapeutics
LEIDEN, the Netherlands, April 20, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that Gerard Platenburg, Chief Innovation Officer, will present at the 42nd Annual...
logo_ProQR-150x150.png
ProQR Announces Annual Meeting of Shareholders
April 10, 2017 07:00 ET | ProQR Therapeutics
LEIDEN, the Netherlands, April 10, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that the Annual General Meeting of Shareholders will be held on Wednesday, May 10,...
logo_ProQR-150x150.png
ProQR Announces the Grant of two Key Patents, protecting QR-010 for Cystic Fibrosis in the US and EU
April 03, 2017 07:00 ET | ProQR Therapeutics
Key Updates ProQR received notice of grant for 2 key patents protecting QR-010 for CF in the US and EU until at least July 2033QR-010 is currently being studied in 64 homozygous F508del patients in a...